Clinical and Experimental Immune Tolerance in Pediatric Liver Transplantation

Pediatric liver transplantation (LT) is a life-saving therapy, uniquely characterized by a favorable immunologic profile and a higher incidence of immune tolerance among long-term survivors. The liver's inherent tolerogenic environment, combined with the immunologic immaturity and thymic activity of children, may promote this phenomenon. Achieving operational tolerance (OT) minimizes lifelong immunosuppression (IS) toxicity, improving allograft longevity and quality of life. This review synthesizes current clinical and mechanistic evidence on immune tolerance in pediatric LT, evaluating the prevalence and outcomes of IS-withdrawal trials (e.g., WISP-R, iWITH, LIFT, OPTIMAL, SPLIT, ALLTOL). It also examines histopathologic correlations, clinical and immunologic predictors, and underlying molecular mechanisms and cell types such as regulatory T-cells, IL-10, TGF-β, CTLA-4 pathways, and so forth. It addresses the challenges and limitations in translating these advances into widespread clinical practice. OT is achievable in 15%-60% of carefully selected pediatric LT recipients in structured IS withdrawal protocols. Tolerant children maintain normal graft function, excellent survival, and preserved immunity without increased infection risk or the cumulative toxicities of chronic IS. Predictors of OT include younger age at transplant or withdrawal, non-immune disease etiology, longer post-transplant duration, and absence of donor-specific antibodies. Mechanistically, the liver's unique microenvironment, characterized by specific molecular pathways and cellular interactions, fosters immune regulation. Immune tolerance in pediatric LT is clinically attainable and significantly reduces the burden of lifelong IS. Progress in biomarker-guided and protocolized withdrawal has improved safety, yet standardization and broader implementation remain challenges. Continued mechanistic and translational research is essential to optimize patient selection, refine monitoring strategies, and safely extend IS minimization to all pediatric LT recipients.